Consequences of the birth
EU leaves the first medication for puerperium depression
The EU allows for the first time to have a medication for now bed depression – it could be relieved for affected mothers. However, not every woman should take the remedy.
Women with puerperium depression will have access to a new medication in the EU in the future. The European Commission has granted the EU-wide market approval, as the authority announced. However, there is a big restriction: the remedy is not recommended for breastfeeding and should not be used during pregnancy.
In the case of puerperium depression – also called postpartum depression (PPD) – mothers can suffer from the symptoms of classic depression, including persistent sadness, fear, tiredness and fatigue. The disease can last for several months and develop into permanent depression in severe cases. This can burden both mother and child.
According to the German depression aid, around 10 to 15 percent of the mothers of PPD are affected. Women who were affected by depressive moods before pregnancy would have a higher risk of symptoms.
Antidepressants did not look fast enough against puerperium depression
So far, there have been no treatments approved for this specific disease, according to the EU Commission on Wednesday. The commission explained that the drug from the Dutch manufacturer Biogen can combat the symptoms of puerperium depression within two weeks. “Standard antidepressants often don’t look fast enough,” said Brussels.
Admission is based on the positive scientific assessment of the European Medicines Agency (EMA). The drug is prescription and can have side effects.
More sources:
Dpa · AFP
MKB
Source: Stern
I’m Caroline, a journalist and author for 24 Hours Worlds. I specialize in health-related news and stories, bringing real-world impact to readers across the globe. With my experience in journalism and writing in both print and online formats, I strive to provide reliable information that resonates with audiences from all walks of life.
